Commercial product exploitation from marine microbial biodiversity: some legal and IP issues.
The biodiversity found in the marine environment is remarkable and yet largely unknown compared with the terrestrial one. The associated genetic resource, also wide and unrevealed, has raised a strong interest from the scientific and industrial community. However, despite this growing interest, the discovery of new compounds extracted from marine organisms, more precisely from microorganisms, is ruled by a complex legislation. The access and transfer of genetic resource are ruled by the Convention on Biological Diversity. One of the three core objectives of this convention is to ensure the fair and equitable sharing of benefits generated by the use of genetic resources and to split these benefits between the different stakeholders. From the discovery of a microorganism to the commercialization of a product, three main stakeholders are involved: providers of microorganisms, e.g. academic institutes, the scientists who will perform R&D on biodiversity, and the industrial companies which will commercialize the final product arising from the R&D results. This article describes how difficult and complex it might be to ensure a fair distribution of benefits of this research between the parties.
Protéus SA, 70 allée Graham Bell, Parc Georges Besse, 30035 Nîmes CEDEX 1, France.
Camille
C
Tichet
Hong Khanh
HK
Nguyen
Sefia El
SE
Yaakoubi
Jean-François
JF
Bloch
D059001:Aquatic Organisms / Q000302:isolation & purification* / Q000378:metabolism; D044822:Biodiversity; D007218:Industrial Microbiology / Q000331:legislation & jurisprudence*; D018973:Intellectual Property; D012106:Research / Q000331:legislation & jurisprudence*; D012623:Seawater / Q000382:microbiology
Science. 2005 Jan 7;307(5706):121-3
15637281
Gene. 1991 Dec 1;108(1):1-6
1761218
Environ Microbiol. 2009 Jun;11(6):1527-39
19226298